RT Journal Article
SR Electronic
T1 High mortality of COVID-19 associated mucormycosis in France: a nationwide retrospective study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.05.21260041
DO 10.1101/2021.07.05.21260041
A1 Danion, François
A1 Letscher-Bru, Valérie
A1 Guitard, Juliette
A1 Sitbon, Karine
A1 Dellière, Sarah
A1 Angoulvant, Adela
A1 Desoubeaux, Guillaume
A1 Botterel, Francoise
A1 Bellanger, Anne-Pauline
A1 Gargala, Gilles
A1 Uhel, Fabrice
A1 Bougnoux, Marie-Elisabeth
A1 Gerber, Victor
A1 Michel, Justin
A1 Cornu, Marjorie
A1 Bretagne, Stéphane
A1 Lanternier, Fanny
A1 the COVID-Mucor study group
YR 2021
UL http://medrxiv.org/content/early/2021/07/07/2021.07.05.21260041.abstract
AB We studied COVID-19 associated mucormycosis based on 17 cases reported nationwide and assessed the differences with India. They differed by frequencies of diabetes mellitus (47% in France versus 95% in India), hematological malignancies (35% versus 1%), anatomical sites (53% lung versus >80% rhino-orbito-cerebral) and prognosis (>80% mortality versus <50%).Competing Interest StatementFD declares personal fees from Gilead outside the submitted work. FL declares personal fees from Gilead and F2G outside the submitted work. Other Authors have nothing to declare.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study is part of the NRCMA official duties which are approved by the Institut Pasteur Internal Review Board (2009-34/IRB) in accordance with French Law.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author